Response to Marc Landers question to the Home Secretary on Cannabis being prescribed on the NHS.

[GrownHealth]

 

[Delta 9]

We all know this is about the clinical trials for intractable, refactory drug resistant epilpesy for kids which is welcome.

this is the type of product the NHS is waiting for with big pharma leading the way after poisoning us for years

https://ocs.ca/products/spark-thc-moonrocks-aspire-1

 

[node]

We all know this is about the clinical trials for intractable, refactory drug resistant epilpesy for kids which is welcome.

this is the type of product the NHS is waiting for with big pharma leading the way after poisoning us for years

https://ocs.ca/products/spark-thc-moonrocks-aspire-1

Thats a great product there.

 

[Delta 9]

Thats a great product there.

it certainly is node

live rosin ones but look at products especially the hash and resin products

SPARK THC Moonrocks - Live Rosin Reserve

SPARK THC Moonrocks - Live Rosin Reserve are fast-acting tablets made for the out-going explorer within. Each package contains 30 (10mg THC) tablets that can be easily split into 5mg THC doses. These tablets are powered by patent pending technology enabling fast onset times, and robust...

ocs.ca

Keeping on track Marc Landers thank you for highlighting and keeping up the fight for it to be prescribed and personal stories do have the biggest impact and writing to your mp can only do some good respect.

 

[GrownHealth]

For Marc Landers Free weekly newsletter and free to download book sign-up below

UK Thread 'Free weekly medical cannabis newsletter'

2nd Oct, 2024

BudMed is a free weekly medical cannabis newsletter.

SUBSCRIBE FOR FREE!

This weeks issue is about Cannabis for Alzheimer’s

Don't miss a single issue! Sent to your email automatically EVERY Thursday at 6pm.

A quick and informative read!

There's still time to sign up for this weeks issue which goes out tomorrow at 6pm. Subscribe here! It's free!

• Marc Landers
• Replies: 2
• Forum: Industry News & Media Coverage

• 
• 

 

[GrownHealth]

The Advisory Council on the Misuse of Drugs will be reviewing CBPM prescribing as part of a three-year programme: